Special Issue

Cardiac Electrophysiology and Pharmacology

Message from the Guest Editors

Cardiac arrhyhtmia is a leading casue of morbidity and mortality; therefore, large efforts in cardiac research have gone into finding appropriate antiarrhythmic drugs in the past few decades. Classical antiarrhythmic therapy includes the application of several Na+-, K+-, and Ca2+-channel blockers. However, the pharmacological interventions are still hampered because the compounds often exert lack of selectivity and/or proarrhyhtmic side-effects. A further important aspect of the unsatisfactory pharmacological treatments is the lack of sufficient knowledge of the underlying mechanisms in several diseases. Better understanding of cardiac electrophysiology, both in health and in disease, could improve the effectiveness of the pharmacological treatments and may decrease the proarrhytmic risk. This Special Issue is designed for those fields of cardiac electrophysiology. pathophysiology, and pharmacology that are critically important to improve the efficacy and safety of antiarrhythmic treatment.

Guest Editors

Dr. Norbert Nagy

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, 6721 Szeged, Hungary

Dr. Norbert Jost

Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, 6721 Szeged, Hungary

Deadline for manuscript submissions

closed (30 September 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/135693

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

